We came across a bullish thesis on uniQure N.V. on Truffle Pigs’s Substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.’s share was trading at $63.65 as of October 9th. QURE’s forward P/E was 27.93 according to Yahoo Finance.
Sergey Nivens/Shutterstock.com
uniQure’s AMT-130 represents a groundbreaking advancement in Huntington’s disease, providing the first credible evidence that a gene therapy can meaningfully alter the course of this fatal...
